Squibb Licenses Acacia Biosciences' Genome Reporter Matrix | GenomeWeb

PRINCETON, NJ--Bristol-Myers Squibb announced it will license the use of Acacia Biosciences' proprietary Genome Reporter Matrix, a technology to identify changes in the expression of thousands of genes in the presence of potential therapeutic compounds. Bristol-Myers Squibb will use the matrix to develop pharmaceutical compound profiles that can help researchers understand the therapeutic benefits and potential side effects of compounds, as well as identify novel targets for drug discovery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.